Skip to main content
Fig. 2 | BMC Urology

Fig. 2

From: Elucidating the need for prostate cancer risk calculators in conjunction with mpMRI in initial risk assessment before prostate biopsy at a tertiary prostate cancer center

Fig. 2

ROC curves for csPCa detection by multivariate risk models and mpMRI in stratified subgroups based on PI-RADS score. ROC curve analysis of PI-RADS score, ERSPC-RC3, MRI-ERSPC-RC3, Radtke-RC and MSP-RC before initial prostate biopsy comparing healthy patients and men with proven csPCa in men with negative mpMRI (negative multiparametric magnetic resonance tomography with PI-RADS (The Prostate Imaging—Reporting and Data System Version 2 (PI-RADS™ v2.1)) score 1–2, A); men with equivocal mpMRI (PI-RADS score 3, B); and men with suspicious mpMRI (PI-RADS score 3–5, C) is shown. The non mpMRI-based ERSPC-RC3 demonstrated favorable diagnostic ability for csPCa in men with negative mpMRI (AUC 0.80). It showed superior performance relative to all other risk models within this subgroup, as evidenced by a significantly higher AUC for ERSPC-RC3 in comparison to Radtke-RC (p = 0.016). In men PI-RADS 3 rated men the PSAD alone showed comparable performance to multivariate risk models (all p > 0.5: compared to Radke-RC, p = 0.538, ERSP-RC3, p = 0.850, MRI-ERSP-RC 3, p = 0.686 and MSP-RC, p = 0.934. Moreover, PSAD predicted csPCa detection better than the PI-RADS score (AUC 0.65 vs. 0.50, p = 0.020)

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us